Clinical Utility of Serial Serum c-erbB-2 Determinations in the Follow-up of Breast Cancer Patients
- 1 September 2002
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 75 (2) , 97-106
- https://doi.org/10.1023/a:1019601022456
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic valueBreast Cancer Research and Treatment, 1998
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patientsBreast Cancer Research and Treatment, 1997
- Serial serum c-erbB-2 levels in patients with breast carcinomaCancer, 1996
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Serum c-erbB-2 in Breast Cancer PatientsActa Oncologica, 1994
- In vitro and in vivo Release of Soluble erbB‐2 Protein from Human Carcinoma CellsJapanese Journal of Cancer Research, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature, 1984